RESUMO
3,3'-Diindolylmethane (DIM), a major phytochemical derived from ingestion of cruciferous vegetables, is also a dietary supplement. In preclinical models, DIM is an effective cancer chemopreventive agent and has been studied in a number of clinical trials. Previous pharmacokinetic studies in preclinical and clinical models have not reported DIM metabolites in plasma or urine after oral dosing, and the pharmacological actions of DIM on target tissues is assumed to be solely via the parent compound. Seven subjects (6 males and 1 female) ranging from 26-65 years of age, on a cruciferous vegetable-restricted diet prior to and during the study, took 2 BioResponse DIM 150-mg capsules (45.3 mg DIM/capsule) every evening for one week with a final dose the morning of the first blood draw. A complete time course was performed with plasma and urine collected over 48 hours and analyzed by UPLC-MS/MS. In addition to parent DIM, two monohydroxylated metabolites and 1 dihydroxylated metabolite, along with their sulfate and glucuronide conjugates, were present in both plasma and urine. Results reported here are indicative of significant phase 1 and phase 2 metabolism and differ from previous pharmacokinetic studies in rodents and humans, which reported only parent DIM present after oral administration. 3-((1H-indole-3-yl)methyl)indolin-2-one, identified as one of the monohydroxylated products, exhibited greater potency and efficacy as an aryl hydrocarbon receptor agonist when tested in a xenobiotic response element-luciferase reporter assay using Hepa1 cells. In addition to competitive phytochemical-drug adverse reactions, additional metabolites may exhibit pharmacological activity highlighting the importance of further characterization of DIM metabolism in humans. SIGNIFICANCE STATEMENT: 3,3'-Diindolylmethane (DIM), derived from indole-3-carbinol in cruciferous vegetables, is an effective cancer chemopreventive agent in preclinical models and a popular dietary supplement currently in clinical trials. Pharmacokinetic studies to date have found little or no metabolites of DIM in plasma or urine. In marked contrast, we demonstrate rapid appearance of mono- and dihydroxylated metabolites in human plasma and urine as well as their sulfate and glucuronide conjugates. The 3-((1H-indole-3-yl)methyl)indolin-2-one metabolite exhibited significant aryl hydrocarbon receptor agonist activity, emphasizing the need for further characterization of the pharmacological properties of DIM metabolites.
Assuntos
Indóis , Administração Oral , Anticarcinógenos/sangue , Anticarcinógenos/farmacocinética , Anticarcinógenos/urina , Cápsulas , Suplementos Nutricionais , Desenvolvimento de Medicamentos , Vias de Eliminação de Fármacos , Feminino , Humanos , Inativação Metabólica/fisiologia , Indóis/sangue , Indóis/farmacocinética , Indóis/urina , Masculino , Pessoa de Meia-Idade , Compostos Fitoquímicos/sangue , Compostos Fitoquímicos/farmacocinética , Compostos Fitoquímicos/urinaRESUMO
A simple and specific, rapid resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for determination of chlorogenic acid in human plasma using neochlorogenic acid as the internal standard. Plasma samples were precipitated with methanol and separated on a Zorbax C18 column (50â¯×â¯2.1â¯mm, i.d. 1.8⯵m) at a flow rate of 0.4â¯mL/min using a gradient mobile phase of methanol-water containing 0.1% formic acid (v/v). The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring in negative ESI mode. The method was fully validated over the concentration range of 10-2000â¯ng/mL. The indicators of inter- and intra-day precision (RSD%) were all within 10.7%, and the accuracy (RE%) was ranged from -3.0% to 10.6%. Moreover, we evaluated this bioanalytical method by re-analysis of incurred samples as an additional measure of assay reproducibility. This method was successfully applied to pharmacokinetic study of CGA in Chinese subjects with advanced solid tumor after intramuscular injection administration of Chlorogenic acid for injection (CAFI).
Assuntos
Anticarcinógenos/sangue , Ácido Clorogênico/análogos & derivados , Ensaios de Triagem em Larga Escala/métodos , Neoplasias/tratamento farmacológico , Ácido Quínico/análogos & derivados , Espectrometria de Massas em Tandem/métodos , Anticarcinógenos/administração & dosagem , Anticarcinógenos/farmacocinética , Área Sob a Curva , China , Ácido Clorogênico/administração & dosagem , Ácido Clorogênico/sangue , Ácido Clorogênico/farmacocinética , Cromatografia Líquida de Alta Pressão/métodos , Relação Dose-Resposta a Droga , Esquema de Medicação , Estabilidade de Medicamentos , Humanos , Injeções Intramusculares , Neoplasias/sangue , Ácido Quínico/administração & dosagem , Ácido Quínico/sangue , Ácido Quínico/farmacocinética , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
Gastric cancer is one of the most common cancers leading to tumor-related deaths worldwide. Chicoric acid (CA) exhibits a variety of protective effects in different diseases. However, its role in regulating tumor progression has not been reported. Autophagy, as a conserved catabolic process, sustains cellular homoeostasis responding to stress to modulate cell fate. In the study, the effects of CA on gastric cancer were investigated. The results indicated that CA treatment markedly reduced the cell viability and induced apoptosis in gastric cancer cells, and prevented tumor growth in an established xenograft gastric cancer model. Furthermore, CA exposure significantly induced autophagy both in gastric cancer cells and tumor samples, as evidenced by the up-regulated expression of LC3II. Moreover, phosphorylated AMP-activated protein kinase (AMPK) and p70S6 kinase (p70s6k) expression were obviously promoted by CA in vitro and in vivo. Importantly, blocking AMPK activation abrogated CA-induced expression of LC3II in gastric cancer cells. In addition, endoplasmic reticulum (ER) stress in tumor samples or cells was markedly induced by CA treatment through promoting the expression of associated signals such as Parkin, protein kinase RNA-like ER kinase (PERK), activating transcription factors 4 (ATF4) and ATF6. Importantly, these effects were abolished by the inhibition of AMPK signaling. Collectively, our findings indicated that CA prevents human gastric cancer progression by inducing autophagy partly through the activation of AMPK, and represents an effective therapeutic strategy against gastric cancer development.
Assuntos
Proteínas Quinases Ativadas por AMP/metabolismo , Anticarcinógenos/farmacologia , Autofagia/efeitos dos fármacos , Ácidos Cafeicos/farmacologia , Estresse do Retículo Endoplasmático/efeitos dos fármacos , Células Epiteliais/efeitos dos fármacos , Neoplasias Gástricas/prevenção & controle , Succinatos/farmacologia , Animais , Anticarcinógenos/sangue , Ácidos Cafeicos/sangue , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Células Epiteliais/metabolismo , Células Epiteliais/patologia , Humanos , Camundongos Endogâmicos BALB C , Camundongos Nus , Ratos , Ratos Sprague-Dawley , Neoplasias Gástricas/metabolismo , Neoplasias Gástricas/patologia , Succinatos/sangueRESUMO
SCOPE: Prenylated chalcones and flavonoids from hop (Humulus lupulus L.), such as 6-prenylnaringenin (6-PN) and 8-prenylnaringenin (8-PN), are investigated for their health beneficial and anticancer activities. We, thus, compare the oral bioavailability and safety of 6-PN and 8-PN in healthy young women and men, and investigated their effects on peripheral blood mononuclear cells (PBMC). METHODS AND RESULTS: A double-blind, placebo-controlled, crossover trial is conducted with 16 healthy volunteers (eight women, eight men) given a single oral dose of 500 mg 6-PN, 8-PN, or placebo in random order. Maximum total concentrations of 6-PN and 8-PN in plasma (Cmax ; 543 and 2834 nmol L-1 ) and their respective area under the plasma concentration-time curve (AUC; 3635 and 15801 nmol L-1 × h) are significantly (5.2- and 4.3-fold) higher for 8-PN than for 6-PN (p Ë 0.05). PBMC for ex vivo experiments are isolated from blood sampled before and 6 h after intake of 6-PN, 8-PN, or placebo. Despite the single-treatment regime and low blood concentrations, both 6-PN and 8-PN increase the survival of PBMC relative to control. CONCLUSION: 8-PN is significantly more bioavailable in healthy humans than its isomer 6-PN. Interestingly, 6-PN, despite being less bioavailable, is similarly effective as 8-PN in enhancing PBMC viability.
Assuntos
Anticarcinógenos/metabolismo , Flavanonas/metabolismo , Flavonoides/metabolismo , Humulus/química , Inflorescência/química , Adulto , Anti-Inflamatórios não Esteroides/efeitos adversos , Anti-Inflamatórios não Esteroides/análise , Anti-Inflamatórios não Esteroides/sangue , Anti-Inflamatórios não Esteroides/metabolismo , Anticarcinógenos/efeitos adversos , Anticarcinógenos/sangue , Anticarcinógenos/síntese química , Sobrevivência Celular , Células Cultivadas , Estudos Cross-Over , Método Duplo-Cego , Feminino , Flavanonas/efeitos adversos , Flavanonas/sangue , Flavanonas/urina , Flavonoides/efeitos adversos , Flavonoides/sangue , Flavonoides/urina , Humanos , Fatores Imunológicos/efeitos adversos , Fatores Imunológicos/sangue , Fatores Imunológicos/metabolismo , Fatores Imunológicos/urina , Absorção Intestinal , Leucócitos Mononucleares/citologia , Leucócitos Mononucleares/imunologia , Leucócitos Mononucleares/metabolismo , Masculino , Valor Nutritivo , Eliminação Renal , Adulto JovemRESUMO
PURPOSE: Glycerol usage is increasing in food industry for human and animal nutrition. This study analyzed the impact of glycerol metabolism when orally supplemented during the early stage of rat liver carcinogenesis. METHODS: Wistar rats were subjected to a 2-phase model of hepatocarcinogenesis (initiated-promoted, IP group). IP animals also received glycerol by gavage (200 mg/kg body weight, IPGly group). RESULTS: Glycerol treatment reduced the volume of preneoplastic lesions by decreasing the proliferative status of liver foci, increasing the expression of p53 and p21 proteins and reducing the expression of cyclin D1 and cyclin-dependent kinase 1. Besides, apoptosis was enhanced in IPGly animals, given by an increment of Bax/Bcl-2 ratio, Bad and PUMA mitochondrial expression, a concomitant increase in cytochrome c release and caspase-3 activation. Furthermore, hepatic levels of glycerol phosphate and markers of oxidative stress were increased in IPGly rats. Oxidative stress intermediates act as intracellular messengers, inducing p53 activation and changes in JNK and Erk signaling pathways, with JNK activation and Erk inhibition. CONCLUSION: The present work provides novel data concerning the preventive actions of glycerol during the development of liver cancer and represents an economically feasible intervention to treat high-risk individuals.
Assuntos
Anticarcinógenos/uso terapêutico , Apoptose , Suplementos Nutricionais , Glicerol/uso terapêutico , Neoplasias Hepáticas Experimentais/prevenção & controle , Estresse Oxidativo , Lesões Pré-Cancerosas/prevenção & controle , Animais , Anticarcinógenos/sangue , Anticarcinógenos/metabolismo , Biomarcadores/sangue , Carcinogênese , Proteínas de Ciclo Celular/genética , Proteínas de Ciclo Celular/metabolismo , Proliferação de Células , Regulação Neoplásica da Expressão Gênica , Glicerol/sangue , Glicerol/metabolismo , Peroxidação de Lipídeos , Fígado/enzimologia , Fígado/metabolismo , Fígado/patologia , Neoplasias Hepáticas Experimentais/sangue , Neoplasias Hepáticas Experimentais/metabolismo , Neoplasias Hepáticas Experimentais/patologia , Sistema de Sinalização das MAP Quinases , Masculino , Mitocôndrias Hepáticas/enzimologia , Mitocôndrias Hepáticas/metabolismo , Mitocôndrias Hepáticas/patologia , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/metabolismo , Fosforilação , Lesões Pré-Cancerosas/sangue , Lesões Pré-Cancerosas/metabolismo , Lesões Pré-Cancerosas/patologia , Ratos Wistar , Carga TumoralRESUMO
Naproxen (nap) is belonging to Non-steriodal anti-inflammatory drugs (NSAIDs) group of drugs that characterized by their free carboxylic group. The therapeutic activity of nap is usually accompanied by GI untoward side effects. Recently synthesized naproxen amides of some amino acid esters prodrugs to mask the free carboxylic group were reported. Those prodrugs showed a promising colorectal cancer chemopreventive activity. The current study aims to investigate the fate and hydrolysis of the prodrugs kinetically in different pH conditions, simulated gastric and intestinal fluids with pHs of 1.2, 5.5 and 7.4 in vitro at 37⯰C. The effect of enzymes on the hydrolysis of prodrugs was also studied through incubation of these prodrugs at 37⯰C in human plasma and rat liver homogenates. The pharmacokinetic parameters of selected prodrugs and the liberated nap were studied after oral and intraperitoneal administration in male wistar rats. The results showed the hydrolysis of naproxen amides of amino acid esters to nap through two steps first by degradation of the ester moiety to form the amide of nap with amino acid and the second was through the degradation of the amide link to liberate nap. The two reactions were followed and studied kinetically where K1 and K2 (rate constants of degradation) is reported. The hydrolysis of prodrugs was faster in liver homogenates than in plasma. The relative bioavailability of the liberated nap in vivo was higher in case of prodrug containing ethyl glycinate moiety than that occupied l-valine ethyl ester moiety. Each of nap. prodrugs containing ethyl glycinate and l-valine ethyl ester moieties appears promising in liberating nap, decreasing direct GI side effect and consequently their colorectal cancer chemopreventive activity.
Assuntos
Amidas/farmacocinética , Aminoácidos/farmacocinética , Anticarcinógenos/farmacocinética , Naproxeno/análogos & derivados , Naproxeno/farmacocinética , Pró-Fármacos/farmacocinética , Administração Oral , Amidas/administração & dosagem , Amidas/sangue , Amidas/química , Aminoácidos/administração & dosagem , Aminoácidos/sangue , Aminoácidos/química , Animais , Anticarcinógenos/administração & dosagem , Anticarcinógenos/sangue , Anticarcinógenos/química , Neoplasias Colorretais/tratamento farmacológico , Estabilidade de Medicamentos , Ésteres/administração & dosagem , Ésteres/sangue , Ésteres/química , Ésteres/farmacocinética , Humanos , Concentração de Íons de Hidrogênio , Hidrólise , Injeções Intraperitoneais , Cinética , Fígado/metabolismo , Masculino , Naproxeno/administração & dosagem , Naproxeno/sangue , Pró-Fármacos/administração & dosagem , Pró-Fármacos/análise , Pró-Fármacos/química , Ratos WistarRESUMO
Resveratrol (RES) is well known natural polyphenol with proven antioxidant, antiinflammatory and anticarcinogenic properties. Since mode of application may be important for cancer-preventive effects of RES, the aim of this study was to evaluate a possible delay in the initiation and progression of chemically induced mammary carcinogenesis in female Sprague-Dawley rats after the nocturnal administration of RES. Application of a high dose of RES (100 mg/kg body weight), starting 2 weeks before the first N-methyl-N-nitrosourea dose (NMU) (50 mg/kg body weight), reduced tumor incidence and markedly prolonged latency period (P < 0.01) in the NMU + RES group in comparison to NMU tumor bearing animals. In addition, the tumor volume decreased significantly (P < 0.05) together with tumor frequency (P < 0.05). We also observed that food but not water intake was significantly reduced by 17% between weeks 4 and 12 in the NMU + RES group leading to a pronounced reduction in the body mass of about 25% as compared to untreated controls. In addition to direct effects of RES in tumor tissues, this polyphenol did also improve metabolic functions in RES-treated animals since it normalizes hypoproteinemia and urea levels and increases the number of lymphocytes when compared with NMU. Higher level of reactive oxygen species (ROS) in leukocytes and the elevation of proinflammatory plasma cytokines IL-1 and IL-2 may contribute to the observed reduction in tumor development. These results indicate for the first time that nocturnal administration of a high dose of RES significantly affects tumor development in vivo. Therefore, we conclude that RES is a promising candidate for cancer chemoprevention. However, it should be noted that the mode of application might significantly affect RES ability to fight cancer.
Assuntos
Anticarcinógenos/administração & dosagem , Neoplasias Mamárias Experimentais/prevenção & controle , Estilbenos/administração & dosagem , Animais , Anticarcinógenos/sangue , Anticarcinógenos/farmacocinética , Anticarcinógenos/uso terapêutico , Carcinógenos , Citocinas/sangue , Esquema de Medicação , Receptor alfa de Estrogênio/metabolismo , Receptor beta de Estrogênio/metabolismo , Feminino , Neoplasias Mamárias Experimentais/induzido quimicamente , Neoplasias Mamárias Experimentais/metabolismo , Neoplasias Mamárias Experimentais/patologia , Metilnitrosoureia , Proteínas Circadianas Period/metabolismo , Ratos Sprague-Dawley , Espécies Reativas de Oxigênio/sangue , Resveratrol , Estilbenos/sangue , Estilbenos/farmacocinética , Estilbenos/uso terapêutico , Carga Tumoral/efeitos dos fármacosRESUMO
Aspirin is an effective analgesic and antiplatelet drug that in addition to its ability to reduce pain, inflammation and fever, appears to have efficacy in the prevention/treatment of a range of diseases including heart disease, numerous cancers and Alzheimer's. It is important to understand the bioavailability of aspirin and its major metabolite, salicylic acid, since dosage and route of administration can vary for treating differing diseases, and the major side-effects of aspirin, upper gastrointestinal ulceration and bleeding, are dose-dependent. We examined the time course for gastroduodenal uptake of aspirin and the appearance of its major metabolite salicylic acid in blood and lymph after intragastric (to simulate oral) and intraduodenal (to simulate enteric-coating) dosing in rats. Results show that after intragastric dosing, intact aspirin is absorbed primarily by the gastric mucosa and to a lesser extent by the duodenal mucosa. When aspirin is dosed intragastrically or intraduodenally, a much greater concentration of aspirin enters the lymph than the blood. In contrast, the concentration of salicylic acid was higher in blood than in lymph. Lymph levels of both aspirin and salicylic acid were sufficiently high so as to perform a pharmacologic function there, possibly as a chemopreventive agent against colon cancer and potentially the metastatic spread of non-gastrointestinal cancers.
Assuntos
Anti-Inflamatórios não Esteroides/farmacocinética , Anticarcinógenos/farmacocinética , Aspirina/farmacocinética , Mucosa Intestinal/metabolismo , Sistema Linfático/metabolismo , Ácido Salicílico/farmacocinética , Animais , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/sangue , Anticarcinógenos/administração & dosagem , Anticarcinógenos/sangue , Aspirina/administração & dosagem , Aspirina/sangue , Disponibilidade Biológica , Vias de Administração de Medicamentos , Masculino , Ratos , Ratos Sprague-Dawley , Ácido Salicílico/administração & dosagem , Ácido Salicílico/sangueRESUMO
Lee W. Wattenberg, who spent his entire career at the University of Minnesota, was a true pioneer in the field of chemoprevention. This paper is a tribute to his groundbreaking research which uncovered the cancer prevention properties of many dietary compounds, including those discussed here in some detail-indole-3-carbinol and diindolylmethane. These compounds occur as glucosinolate conjugates in cruciferous vegetables and are released when one chews or otherwise macerates the vegetable. They have numerous beneficial effects including the ability to prevent cancer in laboratory animals treated with carcinogens. We review some of the early work on indole-3-carbinol and diindolylmethane which spurred subsequent studies on their efficacy and molecular mechanisms of prevention. We also present unique data on field conditions that affect levels of their glucosinolate precursors in vegetables and on the release of diindolylmethane in people who consume cruciferous vegetables.
Assuntos
Brassicaceae/química , Indóis/farmacologia , Neoplasias/prevenção & controle , Verduras , Animais , Anticarcinógenos/sangue , Anticarcinógenos/farmacologia , Benzo(a)pireno/toxicidade , Biomarcadores/urina , Carcinógenos/toxicidade , Linhagem Celular Tumoral , Dieta , Modelos Animais de Doenças , Epigênese Genética , Glucosinolatos/metabolismo , Glucosinolatos/farmacologia , Glucosinolatos/urina , Humanos , Indóis/urina , Pulmão/efeitos dos fármacos , Pulmão/metabolismo , Nitrosaminas/toxicidadeRESUMO
3,3'-Diindolylmethane (DIM) has been investigated as a potential anti-cancer chemopreventive agent in many preclinical and clinical studies. In this study, we sought to characterize the pharmacokinetics of DIM and to build a pharmacokinetic (PK) and pharmacodynamic (PD) model of the DIM-induced gene expression of phase II drug metabolizing enzymes (DME), which potentially links DIM's molecular effects to its in vivo chemopreventive efficacy. DIM (10 mg/kg) was administered intravenously (i.v.) to male Sprague-Dawley rats and blood samples were collected at selected time points for 48 h. The plasma concentration of DIM was determined using a validated HPLC method. The mRNA expression of NQO1, GSTP1 and UGT1A1 in blood lymphocytes was measured using quantitative PCR. An indirect response model was employed to relate the concentration of DIM to the expression of the genes NQO1, GSTP1 and UGT1A1, which were chosen as PD markers for DIM. After i.v. administration, the plasma concentration of DIM declined quickly, and the expression of target genes increased significantly, peaking at 1-2 h and then returning to basal levels after 24 h. The parameters in the PK-PD model were estimated. The PK-PD model aptly described the time delay and magnitude of gene expression induced by DIM. Our results indicate that DIM is effective at inducing various phase II DME, which are capable of detoxify carcinogens. This PK-PD modeling approach provides a framework for evaluating the acute effects of DIM or other similar drugs in clinical trials.
Assuntos
Anticarcinógenos/farmacocinética , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Glucuronosiltransferase/genética , Glutationa S-Transferase pi/genética , Indóis/farmacocinética , Modelos Biológicos , NAD(P)H Desidrogenase (Quinona)/genética , Animais , Anticarcinógenos/sangue , Anticarcinógenos/farmacologia , Indóis/sangue , Indóis/farmacologia , Injeções Intravenosas , Masculino , Desintoxicação Metabólica Fase II , Ratos Sprague-DawleyRESUMO
We evaluated mortality in relation to a panel of autoimmunity-related immunological serum markers in adult patients with epilepsy (PWE), seen in 1996-1997 at the Department of Neurology, Oulu University Hospital in Finland. Blood samples were drawn from 968 volunteers, and baseline measurements included serum immunoglobulins (IgG, IgA, and IgM), and the following antibodies: anticardiolipin, antinuclear, antimitochondrial, antigliadin (IgA and IgG classes), IgA tissue transglutaminase, and IgA endomysial. Hazard ratios (HR) for all-cause mortality in PWE with abnormal immunological markers relative to 413 patients with normal findings were evaluated with adjustment for confounders during a follow-up of nine years. Borderline statistically significant associations were found only for elevated IgA (HR 2.09, 95% CI 0.99-4.42) and for having two or more abnormal antibody titers (HR 1.58, 95% CI 0.98-2.56). The findings of this exploratory study suggested that elevated serum IgA might be associated with excess mortality in PWE.
Assuntos
Autoanticorpos/sangue , Epilepsia , Imunoglobulina A/sangue , Anticorpos Antinucleares/sangue , Anticarcinógenos/sangue , Estudos de Coortes , Epilepsia/sangue , Epilepsia/imunologia , Epilepsia/mortalidade , Feminino , Gliadina/imunologia , Humanos , MasculinoRESUMO
Epidemiological studies support a protective role of lycopene against stroke occurrence or mortality, but the results have been conflicting. We conducted a meta-analysis to assess the relationship between dietary or circulating lycopene and stroke risk (including stroke occurrence or mortality). Relevant papers were collected by screening the PubMed database through October 2013. Only prospective studies providing relative risk estimates with 95% confidence intervals for the association between lycopene and stroke were included. A random-effects model was used to calculate the pooled estimate. Subgroup analysis was conducted to investigate the effects of various factors on the final results. The pooled analysis of seven prospective studies, with 116,127 participants and 1,989 cases, demonstrated that lycopene decreased stroke risk by 19.3% (RR=0.807, 95% CI=0.680-0.957) after adjusting for confounding factors. No heterogeneity was observed (p=0.234, I2=25.5%). Circulating lycopene, not dietary lycopene, was associated with a statistically significant decrease in stroke risk (RR=0.693, 95% CI=0.503-0.954). Lycopene could protect European, or males against stroke risk. Duration of follow-up had no effect on the final results. There was no evidence of publication bias. Lycopene, especially circulating lycopene, is negatively associated with stroke risk.
Assuntos
Anticarcinógenos/sangue , Carotenoides/sangue , Dieta , Acidente Vascular Cerebral/prevenção & controle , Anticarcinógenos/administração & dosagem , Carotenoides/administração & dosagem , Feminino , Humanos , Licopeno , Masculino , Estudos Prospectivos , Risco , Acidente Vascular Cerebral/etiologiaRESUMO
Mifepristone (RU486) is a chemical abortifacient used by hundreds of millions of women world-wide. It has recently been used in clinical trials for psychotic depression and cancer chemotherapy. Metapristone is the most predominant biological active metabolite of mifepristone, and being developed as a novel cancer metastasis chemopreventive agent based on its unique pharmacological properties. In this study, a novel rapid and sensitive method using UPLC/MS/MS was developed and validated for quantitative analysis of metapristone in plasma, which used less plasma volume and was demonstrated to be more simple and low-cost than the published methods. Metapristone in plasma was recovered by liquid-liquid extraction using 1 mL of ethyl acetate and chromatographic separation was carried on a C18 column at 35 °C, with a gradient mobile phase consisting of methanol and water containing 0.1% (v/v) formic acid at a flow rate of 0.3 mL/min. The mass spectrometric detection was carried out using a triple-quadrupole system via positive electrospray ionization. Multiple reaction monitoring was used for quantitation of m/z transitions from 416.3 to 119.9 for metapristone and from 313.1 to 109 for levonorgestrel (internal standard). Good linearity (r²> 0.9926) was achieved over a concentration range from 7.1 to 2840 ng/mL with a lower limit of quantification of 7.1 ng/mL for metapristone. The intra- and inter-day variations of the assay were 2.4-10.0% relative standard deviation with an accuracy of -5.6 to 8.6% relative error. This newly developed method was successfully applied to a pharmacokinetic study that revealed, for the first time, that there was a significant difference in pharmacokinetic profile between genders.
Assuntos
Anticarcinógenos/sangue , Cromatografia Líquida de Alta Pressão/métodos , Mifepristona/análogos & derivados , Espectrometria de Massas em Tandem/métodos , Animais , Feminino , Limite de Detecção , Masculino , Mifepristona/sangue , Ratos , Ratos Sprague-DawleyRESUMO
Methyleugenol (ME) occurs naturally in a variety of spices, herbs, including basil, and their essential oils. ME induces hepatomas in rodent bioassays following its conversion to a DNA reactive metabolite. In the present study, the basil constituent nevadensin was shown to be able to inhibit SULT-mediated DNA adduct formation in HepG2 cells exposed to the proximate carcinogen 1'-hydroxymethyleugenol in the presence of nevadensin. To investigate possible in vivo implications of SULT inhibition by nevadensin on ME bioactivation, the rat physiologically based kinetic (PBK) model developed in our previous work to describe the dose-dependent bioactivation and detoxification of ME in male rat was combined with the recently developed PBK model describing the dose-dependent kinetics of nevadensin in male rat. The resulting binary ME-nevadensin PBK model was used to predict the possible nevadensin mediated reduction in ME DNA adduct formation and resulting carcinogenicity at the doses of ME used by the NTP carcinogenicity study. Using these data an updated risk assessment using the Margin of Exposure (MOE) approach was performed. The results obtained point at a potential reduction of the cancer risk when rodents are orally exposed to ME within a relevant food matrix containing SULT inhibitors compared to exposure to pure ME.
Assuntos
Anticarcinógenos/farmacologia , Carcinógenos/farmacocinética , Eugenol/análogos & derivados , Flavonas/farmacologia , Hepatócitos/metabolismo , Modelos Biológicos , Animais , Anticarcinógenos/sangue , Anticarcinógenos/metabolismo , Anticarcinógenos/farmacocinética , Biotransformação/efeitos dos fármacos , Carcinógenos/administração & dosagem , Carcinógenos/metabolismo , Carcinógenos/toxicidade , Adutos de DNA/antagonistas & inibidores , Adutos de DNA/metabolismo , Relação Dose-Resposta a Droga , Inibidores Enzimáticos/sangue , Inibidores Enzimáticos/metabolismo , Inibidores Enzimáticos/farmacocinética , Inibidores Enzimáticos/farmacologia , Eugenol/administração & dosagem , Eugenol/metabolismo , Eugenol/farmacocinética , Eugenol/toxicidade , Feminino , Flavonas/sangue , Flavonas/metabolismo , Flavonas/farmacocinética , Células Hep G2 , Hepatócitos/efeitos dos fármacos , Hepatócitos/enzimologia , Humanos , Masculino , Ratos , Ratos Endogâmicos F344 , Ratos Sprague-Dawley , Medição de Risco , Sulfotransferases/antagonistas & inibidores , Sulfotransferases/metabolismo , Distribuição Tecidual/efeitos dos fármacosRESUMO
BACKGROUND: In the Chenopodiaceae family, the apigenin flavonoids vitexin-2-O-xyloside (VOX) and vitexin-2-O-rhamnoside (VOR) are important chemopreventive components. To investigate their bioavailability in in vivo animal studies an enzyme-linked immunosorbent assay (ELISA) method has been developed. RESULTS: The ELISA was based on polyclonal antibodies elicited in mice by injecting, as an immunogen, 4',6â³-O-biapigenin (hinokiflavone, HF) conjugated to bovine serum albumin (BSA-HF). A second immunogen was synthesised by coupling an equimolar mixture of VOX and VOR to BSA (BSA-F1). The BSA-HF elicited a significant antibody response, due to 17 HF hapten groups, coupled to each BSA molecule, whereas BSA-F1 provided a very low antigenicity in respect to control animals. Antiserum raised against BSA-HF showed an antibody titre of 1:1600. Antibodies were found to be specific for the flavonols. Our results show that VOX and its metabolic products reached the concentration of 3.42 ± 0.72 µg mL⻹ in plasma of VOX fed animals, at the net of the control value. CONCLUSIONS: By using the ELISA, the concentration of apigenin flavonoids and their metabolites can be detected in VOX- or VOR-supplemented animals. The assay represents a useful tool for rapid screening to compare bioavailability of apigenin flavonoids in respect to control animals.
Assuntos
Anticarcinógenos/farmacocinética , Apigenina/farmacocinética , Flavonoides/sangue , Glicosídeos/farmacocinética , Animais , Anticarcinógenos/sangue , Apigenina/sangue , Biflavonoides/análise , Disponibilidade Biológica , Biotransformação , Calibragem , Ensaio de Imunoadsorção Enzimática , Flavonoides/farmacocinética , Glicosídeos/sangue , Haptenos , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Distribuição AleatóriaRESUMO
Naturally occurring sulforaphane (SF) has been extensively studied for cancer prevention. However, little is known as to which organs may be most affected by this agent, which impedes its further development. In the present study, SF was administered to rats orally either in a single dose or once daily for 7 d. Tissue distribution of SF was measured by a HPLC-based method. Glutathione S-transferase (GST) and NAD(P)H:quinone oxidoreductase 1 (NQO1), two well-known cytoprotective phase 2 enzymes, were measured using biochemical assays to assess tissue response to SF. SF was delivered to different organs in vastly different concentrations. Tissue uptake of SF was the greatest in the stomach, declining rapidly in the descending gastro-intestinal tract. SF was rapidly eliminated through urinary excretion, and urinary concentrations of SF equivalents were 2-4 orders of magnitude higher than those of plasma. Indeed, tissue uptake level of SF in the bladder was second only to that in the stomach. Tissue levels of SF in the colon, prostate and several other organs were very low, compared to those in the bladder and stomach. Moreover, induction levels of GST and NQO1 varied by 3- to 6-fold among the organs of SF-treated rats, though not strictly correlated with tissue exposure to SF. Thus, there is profound organ specificity in tissue exposure and response to dietary SF, suggesting that the potential chemopreventive benefit of dietary SF may differ significantly among organs. These findings may provide a basis for prioritising organs for further chemopreventive study of SF.
Assuntos
Anticarcinógenos/metabolismo , Brassica/química , Mucosa Gástrica/metabolismo , Componentes Aéreos da Planta/química , Tiocianatos/metabolismo , Bexiga Urinária/metabolismo , Administração Oral , Animais , Anticarcinógenos/administração & dosagem , Anticarcinógenos/sangue , Anticarcinógenos/urina , Cromatografia Líquida de Alta Pressão , Indução Enzimática , Glutationa Transferase/biossíntese , Isotiocianatos , Cinética , Masculino , Desintoxicação Metabólica Fase II , NAD(P)H Desidrogenase (Quinona)/biossíntese , Especificidade de Órgãos , Distribuição Aleatória , Ratos , Ratos Endogâmicos F344 , Estômago/enzimologia , Sulfóxidos , Tiocianatos/administração & dosagem , Tiocianatos/sangue , Tiocianatos/urina , Distribuição Tecidual , Bexiga Urinária/enzimologiaRESUMO
Tomatoes may have beneficial effects on prostate health. Efficacy trials would require long-term adherence to high levels of tomato product (TP) consumption. Therefore, factors that affect adherence in men most at risk and whether increased consumption of TP negatively affects diet and health are important concerns. Cancer-free AfricanAmerican (AA) men (n 36) with mean serum prostate-specific antigen of 7.4 SD 5.6) ng/ml were randomised to consume one serving of TP/d or a control diet for 3 months. Mean intervention group lycopene intake rose to 464%, with negligible control group increase. Plasma lycopene levels rose by 53 and 40% in the intervention group in months 1 and 3, respectively (P < 0.0001), with no control group change. The intervention group's barriers to adherence score was inversely associated with both dietary (r -0.49, P = 0.02) and plasma lycopene concentration (r -0.37, P = 0.02). Their TP disadvantage score negatively correlated with the 3-month plasma lycopene concentrations (r -0.37, P = 0.008) and their weekly incentives and impediments were remarkably stable, 'concern for prostate health' being the most consistent over time. 'Liking tomatoes' and 'study participation' decreased in citation frequency at weeks 6 and 9, respectively. No major shifts occurred in dietary cholesterol or saturated fat, with no adverse effects on gastrointestinal complaints, serum total cholesterol, body weight or blood pressure. Lower socio-economic status AA men at higher prostate cancer risk can successfully achieve a whole food intervention goal with a corresponding rise in plasma lycopene concentrations, with no adverse effects on self-selected diet quality or health parameters.
Assuntos
Anticarcinógenos/sangue , Carotenoides/sangue , Dieta/métodos , Cooperação do Paciente , Antígeno Prostático Específico/sangue , Neoplasias da Próstata/etnologia , Solanum lycopersicum , Negro ou Afro-Americano , Idoso , Análise de Variância , Humanos , Licopeno , Solanum lycopersicum/efeitos adversos , Solanum lycopersicum/química , Masculino , Pessoa de Meia-Idade , Neoplasias da Próstata/prevenção & controle , Inquéritos e QuestionáriosRESUMO
BACKGROUND: Carotenoids, micronutrients in fruits and vegetables, may reduce breast cancer risk. Most, but not all, past studies of circulating carotenoids and breast cancer have found an inverse association with at least one carotenoid, although the specific carotenoid has varied across studies. METHODS: We conducted a pooled analysis of eight cohort studies comprising more than 80% of the world's published prospective data on plasma or serum carotenoids and breast cancer, including 3055 case subjects and 3956 matched control subjects. To account for laboratory differences and examine population differences across studies, we recalibrated participant carotenoid levels to a common standard by reassaying 20 plasma or serum samples from each cohort together at the same laboratory. Using conditional logistic regression, adjusting for several breast cancer risk factors, we calculated relative risks (RRs) and 95% confidence intervals (CIs) using quintiles defined among the control subjects from all studies. All P values are two-sided. RESULTS: Statistically significant inverse associations with breast cancer were observed for α-carotene (top vs bottom quintile RR = 0.87, 95% CI = 0.71 to 1.05, P(trend) = .04), ß-carotene (RR = 0.83, 95% CI = 0.70 to 0.98, P(trend) = .02), lutein+zeaxanthin (RR = 0.84, 95% CI = 0.70 to 1.01, P(trend) = .05), lycopene (RR = 0.78, 95% CI = 0.62 to 0.99, P(trend) = .02), and total carotenoids (RR = 0.81, 95% CI = 0.68 to 0.96, P(trend) = .01). ß-Cryptoxanthin was not statistically significantly associated with risk. Tests for heterogeneity across studies were not statistically significant. For several carotenoids, associations appeared stronger for estrogen receptor negative (ER(-)) than for ER(+) tumors (eg, ß-carotene: ER(-): top vs bottom quintile RR = 0.52, 95% CI = 0.36 to 0.77, P(trend) = .001; ER(+): RR = 0.83, 95% CI = 0.66 to 1.04, P(trend) = .06; P(heterogeneity) = .01). CONCLUSIONS: This comprehensive prospective analysis suggests women with higher circulating levels of α-carotene, ß-carotene, lutein+zeaxanthin, lycopene, and total carotenoids may be at reduced risk of breast cancer.
Assuntos
Anticarcinógenos/sangue , Neoplasias da Mama/epidemiologia , Neoplasias da Mama/prevenção & controle , Carotenoides/sangue , Adulto , Idoso , Neoplasias da Mama/sangue , Estudos de Casos e Controles , Cromatografia Líquida de Alta Pressão/métodos , Comportamento Cooperativo , Feminino , Frutas , Humanos , Modelos Logísticos , Luteína/sangue , Licopeno , Pessoa de Meia-Idade , Análise Multivariada , Razão de Chances , Estudos Prospectivos , Medição de Risco , Fatores de Risco , Verduras , Xantofilas/sangue , Zeaxantinas , beta Caroteno/sangueRESUMO
INTRODUCTION: An inverse relationship between some chronic degenerative diseases and plasma lycopene levels has been demonstrated. Dietary intake questionnaires are one of the current methods most used to ascertain dietary patterns and explore their association with the disease risk. The main drawback of their use is the need for previous validation. The purpose of this study was to validate a frequency questionnaire in order to assess the intake of licopene, in the population of the Canary Islands. METHODS: A food intake frequency questionnaire was designed and administered to 70 patients of the Plastic Surgery Service of the Hospital Universitario Insular de Gran Canaria. Estimated lycopene intake from the food intake frequency questionnaire was examined in relation to plasma lycopene levels, measured by HPLC. RESULTS: The Spearman correlation coefficient between estimated lycopene intake and plasma levels was 0,421 and the validity of the questionnaire was demonstrated. Furthermore, an association between obesity and some pathologies with plasma lycopene levels was observed, although not statistically significant. CONCLUSIONS: The food intake frequency questionnaire is valid and it could be useful in epidemiological studies in the population of the Canary Islands.
Assuntos
Anticarcinógenos/administração & dosagem , Antioxidantes/administração & dosagem , Carotenoides/administração & dosagem , Inquéritos e Questionários , Adulto , Idoso , Anticarcinógenos/sangue , Carotenoides/sangue , Cromatografia Líquida de Alta Pressão , Inquéritos sobre Dietas , Ingestão de Alimentos , Comportamento Alimentar , Feminino , Humanos , Licopeno , Masculino , Pessoa de Meia-Idade , Neoplasias/epidemiologia , Obesidade , EspanhaRESUMO
BACKGROUND: Previous evidence suggests that 25-hydroxyvitamin D(3) [25(OH)D(3)] protects against several cancers. However, little is known regarding urothelial bladder cancer (UBC). We analyzed the association between plasma 25(OH)D(3) and overall risk of UBC, as well as according to stage and FGFR3 molecular subphenotypes. METHODS: Plasma concentrations of 25(OH)D(3) in 1125 cases with UBC and 1028 control subjects were determined by a chemiluminescence immunoassay. FGFR3 mutational status and expression in tumor tissue were assessed. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by logistic regression adjusting for potential confounders. Analyses were further stratified by tumor invasiveness and grade, FGFR3 expression, and smoking status. Cell proliferation was measured in human UBC cell lines cultured with 1α,25-dihydroxyvitamin D(3). RESULTS: A statistically significantly increased risk of UBC was observed among subjects presenting the lowest concentrations of 25(OH)D(3) (OR(adj) = 1.83; 95% CI = 1.19 to 2.82; P = .006), showing a dose-response effect (P (trend) = .004). The association was stronger for patients with muscle-invasive tumors, especially among low-FGFR3 expressers (OR(adj) = 5.94; 95% CI = 1.72 to 20.45; P = .005). The biological plausibility of these associations is supported by the fact that, in vitro, 1α,25-dihydroxyvitamin D(3) upregulates FGFR3 expression in UBC cell lines with low levels of wild-type FGFR3. CONCLUSION: These findings support a role of vitamin D in the pathogenesis of UBC and show that 25(OH)D(3) levels are associated with FGFR3 expression in the tumor. Because FGFR3 mutation and overexpression are markers of better outcome, our findings suggest that individuals with low levels of plasma 25(OH)D(3) may be at high risk of more aggressive forms of UBC.